SBIR-STTR Award

Microfluidic Selection Of Monoclonal Antibodies
Award last edited on: 10/13/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$111,350
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Michael P Weiner

Company Information

Affomix Inc (AKA: Affomix Corporation)

300 George Street Suite 305
New Haven, CT 06511
   (203) 481-6400
   N/A
   www.affomix.com
Location: Single
Congr. District: 03
County: New Haven

Phase I

Contract Number: 1R43GM084534-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2008
Phase I Amount
$111,350
Nearly 20 years ago, partially as a response to leveraging the genomics research the NIH invested in the development of gene array technologies. These `gene chips' enabled great breakthroughs in our understanding of the underlying biological processes that occur in cells and tissues. These increased understandings have already led to new therapies that affect the way we now successfully treat and diagnose major diseases, including cancer, diabetes and Alzheimer's. But genes have always been a poor surrogate for what scientists are really eager to understand; the protein make-up and interactions occurring both within and between cells and tissues. In this proposal we describe a microfluidics-based method for obtaining antibodies and affinity-reagents that can be developed for making antibody arrays. We want to develop an inexpensive high-throughput means of selecting and identifying antibodies to both unmodified and modified protein and peptide antigens. The successful completion of this STTR and our future goals will have significant direct impact on the development of new therapeutic targets, new immunotherapeutics, and prognostics and diagnostic biomarkers.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----